These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2362605)

  • 1. Lipophosphoglycan expression and virulence in ricin-resistant variants of Leishmania major.
    Elhay M; Kelleher M; Bacic A; McConville MJ; Tolson DL; Pearson TW; Handman E
    Mol Biochem Parasitol; 1990 May; 40(2):255-67. PubMed ID: 2362605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ricin-resistant mutants of Leishmania major which express modified lipophosphoglycan remain infective for mice.
    Cappai R; Morris L; Aebischer T; Bacic A; Curtis JM; Kelleher M; McLeod KS; Moody SF; Osborn AH; Handman E
    Parasitology; 1994 May; 108 ( Pt 4)():397-405. PubMed ID: 8008453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of lipophosphoglycan from a ricin-resistant mutant of Leishmania major.
    Opat A; Ng K; Currie G; Handman E; Bacic A
    Glycobiology; 1996 Jun; 6(4):387-97. PubMed ID: 8842702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a ricin-resistant mutant of Leishmania donovani that expresses lipophosphoglycan.
    Phillips MR; Turco SJ
    Glycobiology; 2015 Apr; 25(4):428-37. PubMed ID: 25472443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epitope mapping of monoclonal antibodies directed against lipophosphoglycan of Leishmania major promastigotes.
    Kelleher M; Curtis JM; Sacks DL; Handman E; Bacic A
    Mol Biochem Parasitol; 1994 Aug; 66(2):187-200. PubMed ID: 7808469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunochemical structure and surface arrangement of Leishmania donovani lipophosphoglycan determined using monoclonal antibodies.
    Tolson DL; Turco SJ; Beecroft RP; Pearson TW
    Mol Biochem Parasitol; 1989 Jun; 35(2):109-18. PubMed ID: 2475775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An antigenically distinct lipophosphoglycan on amastigotes of Leishmania major.
    Glaser TA; Moody SF; Handman E; Bacic A; Spithill TW
    Mol Biochem Parasitol; 1991 Apr; 45(2):337-44. PubMed ID: 1710036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of entry of virulent and avirulent strains of Leishmania donovani into macrophages: a possible role of virulence molecules (gp63 and LPG).
    Chakrabarty R; Mukherjee S; Lu HG; McGwire BS; Chang KP; Basu MK
    J Parasitol; 1996 Aug; 82(4):632-5. PubMed ID: 8691373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipophosphoglycan is not required for infection of macrophages or mice by Leishmania mexicana.
    Ilg T
    EMBO J; 2000 May; 19(9):1953-62. PubMed ID: 10790362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a macrophage-binding determinant on lipophosphoglycan from Leishmania major promastigotes.
    Kelleher M; Bacic A; Handman E
    Proc Natl Acad Sci U S A; 1992 Jan; 89(1):6-10. PubMed ID: 1370357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of a repeating phosphorylated disaccharide lipophosphoglycan epitope on the surface of macrophages infected with Leishmania donovani.
    Tolson DL; Turco SJ; Pearson TW
    Infect Immun; 1990 Nov; 58(11):3500-7. PubMed ID: 1699895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbohydrate and LPG expression in Leishmania viannia subgenus.
    Muskus C; Segura I; Oddone R; Turco SJ; Leiby DA; Toro L; Robledo S; Saravia NG
    J Parasitol; 1997 Aug; 83(4):671-8. PubMed ID: 9267410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmania major: expression and gene structure of the glycoprotein 63 molecule in virulent and avirulent clones and strains.
    Murray PJ; Handman E; Glaser TA; Spithill TW
    Exp Parasitol; 1990 Oct; 71(3):294-304. PubMed ID: 2209787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of lipophosphoglycan-associated epitopes in different Leishmania species and in African trypanosomes.
    Tolson DL; Schnur LF; Jardim A; Pearson TW
    Parasitol Res; 1994; 80(6):537-42. PubMed ID: 7528916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan.
    Halliday A; Bates PA; Chance ML; Taylor MJ
    Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the defect in lipophosphoglycan biosynthesis in a non-pathogenic strain of Leishmania major.
    McConville MJ; Homans SW
    J Biol Chem; 1992 Mar; 267(9):5855-61. PubMed ID: 1532574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmania promastigotes require lipophosphoglycan to actively modulate the fusion properties of phagosomes at an early step of phagocytosis.
    Dermine JF; Scianimanico S; Privé C; Descoteaux A; Desjardins M
    Cell Microbiol; 2000 Apr; 2(2):115-26. PubMed ID: 11207568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of Leishmania lipophosphoglycan: inter- and intra-specific polymorphism in Old World species.
    McConville MJ; Schnur LF; Jaffe C; Schneider P
    Biochem J; 1995 Sep; 310 ( Pt 3)(Pt 3):807-18. PubMed ID: 7575413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of Leishmania major-infected macrophages by use of lipophosphoglycan-specific monoclonal antibodies.
    Handman E
    Infect Immun; 1990 Jul; 58(7):2297-302. PubMed ID: 1694823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmania expressed lipophosphoglycan interacts with Toll-like receptor (TLR)-2 to decrease TLR-9 expression and reduce anti-leishmanial responses.
    Srivastava S; Pandey SP; Jha MK; Chandel HS; Saha B
    Clin Exp Immunol; 2013 Jun; 172(3):403-9. PubMed ID: 23600828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.